Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

340 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial.
Dezentjé VO, Gelderblom H, Van Schaik RH, Vletter-Bogaartz JM, Van der Straaten T, Wessels JA, Kranenbarg EM, Berns EM, Seynaeve C, Putter H, Van de Velde CJ, Nortier JW, Guchelaar HJ. Dezentjé VO, et al. Among authors: seynaeve c. Breast Cancer Res Treat. 2014 Jan;143(1):171-9. doi: 10.1007/s10549-013-2777-6. Epub 2013 Nov 22. Breast Cancer Res Treat. 2014. PMID: 24265036
Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial.
van de Velde CJ, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel JM, Paridaens R, Markopoulos C, Hozumi Y, Hille ET, Kieback DG, Asmar L, Smeets J, Nortier JW, Hadji P, Bartlett JM, Jones SE. van de Velde CJ, et al. Among authors: seynaeve c. Lancet. 2011 Jan 22;377(9762):321-31. doi: 10.1016/S0140-6736(10)62312-4. Lancet. 2011. PMID: 21247627 Clinical Trial.
Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer - a TEAM study analysis.
van de Water W, Fontein DB, van Nes JG, Bartlett JM, Hille ET, Putter H, Robson T, Liefers GJ, Roumen RM, Seynaeve C, Dirix LY, Paridaens R, Kranenbarg EM, Nortier JW, van de Velde CJ. van de Water W, et al. Among authors: seynaeve c. Eur J Cancer. 2013 Jan;49(2):297-304. doi: 10.1016/j.ejca.2012.07.026. Epub 2012 Sep 3. Eur J Cancer. 2013. PMID: 22954666 Free article. Clinical Trial.
Elderly postmenopausal patients with breast cancer are at increased risk for distant recurrence: a tamoxifen exemestane adjuvant multinational study analysis.
van de Water W, Seynaeve C, Bastiaannet E, Markopoulos C, Jones SE, Rea D, Hasenburg A, Putter H, Hille ET, Paridaens R, de Craen AJ, Westendorp RG, van de Velde CJ, Liefers GJ. van de Water W, et al. Among authors: seynaeve c. Oncologist. 2013;18(1):8-13. doi: 10.1634/theoncologist.2012-0315. Epub 2012 Dec 20. Oncologist. 2013. PMID: 23263290 Free PMC article. Clinical Trial.
Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis.
Fontein DB, Seynaeve C, Hadji P, Hille ET, van de Water W, Putter H, Kranenbarg EM, Hasenburg A, Paridaens RJ, Vannetzel JM, Markopoulos C, Hozumi Y, Bartlett JM, Jones SE, Rea DW, Nortier JW, van de Velde CJ. Fontein DB, et al. Among authors: seynaeve c. J Clin Oncol. 2013 Jun 20;31(18):2257-64. doi: 10.1200/JCO.2012.45.3068. Epub 2013 Apr 22. J Clin Oncol. 2013. PMID: 23610112
Effect of local therapy on locoregional recurrence in postmenopausal women with breast cancer in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial.
van Hezewijk M, Bastiaannet E, Putter H, Scholten AN, Liefers GJ, Rea D, Hasenburg A, Paridaens R, Hozumi Y, Markopoulos C, Seynaeve C, Jones SE, Marijnen CA, van de Velde CJ. van Hezewijk M, et al. Among authors: seynaeve c. Radiother Oncol. 2013 Aug;108(2):190-6. doi: 10.1016/j.radonc.2013.08.020. Epub 2013 Sep 14. Radiother Oncol. 2013. PMID: 24044798 Clinical Trial.
Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial.
Fontein DB, Houtsma D, Nortier JW, Baak-Pablo RF, Kranenbarg EM, van der Straaten TR, Putter H, Seynaeve C, Gelderblom H, van de Velde CJ, Guchelaar HJ. Fontein DB, et al. Among authors: seynaeve c. Breast Cancer Res Treat. 2014 Apr;144(3):599-606. doi: 10.1007/s10549-014-2873-2. Epub 2014 Mar 4. Breast Cancer Res Treat. 2014. PMID: 24590773 Clinical Trial.
Minimal impact of adjuvant exemestane or tamoxifen treatment on mammographic breast density in postmenopausal breast cancer patients: a Dutch TEAM trial analysis.
van Nes JG, Beex LV, Seynaeve C, Putter H, Sramek A, Lardenoije S, Duijm-de Carpentier M, Van Rongen I, Nortier JW, Zonderland HM, van de Velde CJ. van Nes JG, et al. Among authors: seynaeve c. Acta Oncol. 2015 Mar;54(3):349-60. doi: 10.3109/0284186X.2014.964809. Epub 2014 Nov 10. Acta Oncol. 2015. PMID: 25383451 Clinical Trial.
Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial.
Derks MGM, Blok EJ, Seynaeve C, Nortier JWR, Kranenbarg EM, Liefers GJ, Putter H, Kroep JR, Rea D, Hasenburg A, Markopoulos C, Paridaens R, Smeets JBE, Dirix LY, van de Velde CJH. Derks MGM, et al. Among authors: seynaeve c. Lancet Oncol. 2017 Sep;18(9):1211-1220. doi: 10.1016/S1470-2045(17)30419-9. Epub 2017 Jul 18. Lancet Oncol. 2017. PMID: 28732650 Clinical Trial.
Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial.
Schilder CM, Seynaeve C, Beex LV, Boogerd W, Linn SC, Gundy CM, Huizenga HM, Nortier JW, van de Velde CJ, van Dam FS, Schagen SB. Schilder CM, et al. Among authors: seynaeve c. J Clin Oncol. 2010 Mar 10;28(8):1294-300. doi: 10.1200/JCO.2008.21.3553. Epub 2010 Feb 8. J Clin Oncol. 2010. PMID: 20142601
340 results